ArticleNature communications2026
NPM3 functions as a lactyltransferase to promote necroptosis in male diabetic cardiomyopathy mice models via FASN transcription modulation.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lactate in ruminant health: metabolic roles and the emerging significance of lactylation.Journal of animal science and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic cardiomyopathy (DCM) is characterized by diastolic dysfunction, which progresses to heart failure and abnormal electrophysiological changes in patients with diabetes. Lactate-mediated histone lactylation has been implicated in DCM pathogenesis. We investigated the mechanisms by which lactate-mediated histone-H3-lysine-18 lactylation (H3K18la) and H3K27la promote necroptosis in male DCM mice models. Lactate-mediated H3K18la and H3K27la participate in necroptosis via modulating fatty acid synthase (FASN) transcription in DCM. Moreover, Nucleophosmin/nucleoplasmin-3 (NPM3), identified as a lactyltransferase, regulated H3K18la and H3K27la, thereby activating FASN transcription and triggering necroptosis. Furthermore, dihydroartemisinin (DHA) inhibited NPM3 lactyltransferase activity by competing for binding sites between lactate and NPM3. Importantly, DHA treatment reduced the expression of NPM3, H3K18la, H3K27la, and FASN; alleviated necroptosis and cardiac tissue damage; and resolved diastolic dysfunction and ventricular hypertrophy in DCM models. In conclusion, NPM3 acts as a lactyltransferase to modulate FASN transcription, thereby triggering necroptosis. Moreover, inhibiting NPM3-induced histone lactylation via DHA represents an efficacious therapeutic strategy for DCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.